Merck licenses Chinese cancer drug

Merck signs up to $3.3 bln cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday.
Merck Snags Chinese Cancer Drug in Deal Worth Up to $3.3 Billion
Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront, plus as much as $2.7 billion in milestone payments.
Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from LaNova Medicines, a Shanghai-based firm, for $588 million upfront and as much as $2.7 billion in potential milestone payments.
Merck signs up to $3.3 billion cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday. The deal allows Merck to take over development of LaNova's LM-299,
Merck to buy rights to Chinese cancer drug for up to $3.3B
Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected to obtain licensing rights to a cancer candidate known as LM-299 from the Chinese biotech in a deal worth up to $3.
Pharmalittle: We’re reading about a Merck deal, GSK cancer drug data, and more
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company
The University of Chicago Chronicle3h
Argonne, UChicago partner to accelerate discovery of new cancer therapies using AI
“Patients with cancer don’t have time to wait for new treatments, so there is a strong need to compress the drug ...
Cancer patient in Wales denied life-extending drug
A woman whose cancer has spread to her bones, back, pelvis and neck but has been denied a life-extending drug because she lives in Wales says she "wants a chance to live". Rachel Davies, 40, from ...
Drug Combination Prompts Immune Response in Some Resistant Pancreatic Cancers
In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...
Crain's Chicago Business3h
UChicago to harness Argonne's AI, supercomputer tools for cancer drug discovery
With a federal grant in hand, researchers at the health system and national lab will try to hit fast forward on the long and ...
New RAS Gene Discovery Unveils Hidden Pathway Driving Cancer Growth
These findings could pave the way for new treatment approaches for cancers driven by RAS mutations. Researchers at the ...
Genetic variation enhances cancer drug sensitivity in specific patient groups, study shows
By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against ...
GSK’s Withdrawn Blood Cancer Drug Reduced Risk of Death in Trial
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
Welsh cancer patient denied life-extending drug
She has been denied a life-extending drug because she lives in Wales. The drug, called Enhertu, can give patients with a ...
Radio Iowa2d
UI is crafting a new drug to treat ovarian cancer
University of Iowa researchers have landed a $10-million federal grant to develop a new treatment for ovarian cancer. Jill ...